A Cleveland Clinic psychiatrist on how ketamine therapy is transforming depression treatment—and why it works when other options fall short.

Silent synapses are dormant neural connections that hold untapped brain potential. Discover how ketamine, exercise, and other ...

Discover recent clinical trial failures in depression and explore potential pathways for advancing antidepressant drug ...

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand ...

Q4 2024 Earnings Call Transcript March 17, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the NRx ...

Ketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, has emerged as a promising treatment for TRD. Originally an anesthetic, ketamine has shown rapid antidepressant effects ...

Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals 4Q and full year 2024 earnings call. At this time, all lines are in a listen only mode. Following the presentation, we will ...

Ketamine, for example ... Now let's discuss NRX-101, our oral combination of cycloserine and NMDA receptor blocker and lurasidone, the standard of care in bipolar depression.

Ketamine has gained attention for its depression ... The company stands out for its innovative use of NMDA receptor modulators and atypical antipsychotics to treat mental health disorders.

Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...